Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Based on a multitarget strategy, a series of novel chromanone–1-benzyl-1,2,3,6-tetrahydropyridin hybrids were identified for the potential treatment of Alzheimer’s disease (AD). Biological evaluation demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B). The optimal compound C10 possessed excellent dual AChE/MAO-B inhibition both in terms of potency and equilibrium (AChE: IC 50 = 0.58 ± 0.05 μM; MAO-B: IC 50 = 0.41 ± 0.04 μM). Further molecular modeling and kinetic investigations revealed that compound C10 was a dual-binding inhibitor bound to both the catalytic anionic site and peripheral anionic site of AChE. In addition, compound C10 exhibited low neurotoxicity and potently inhibited AChE enzymatic activity. Furthermore, compound C10 more effectively protected against mitochondrial dysfunction and oxidation than donepezil, strongly inhibited AChE-induced amyloid aggregation, and moderately reduced glutaraldehyde-induced phosphorylation of tau protein in SH-SY5Y cells. Moreover, compound C10 displayed largely enhanced improvements in cognitive behaviors and spatial memory in a scopolamine-induced AD mice model with better efficacy than donepezil. Overall, the multifunctional profiles of compound C10 suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ladostigil (46), an AChE/MAO-B inhibitor developed through a pharmacophore fusion strategy,532 has completed a clinical phase II trial (NCT01429623). The trial aimed to evaluate the safety and efficacy of low-dose ladostigil (46) in patients with MCI. The results indicated that the drug was well-tolerated and safe, seemingly possessing the potential to delay the progression of AD.533”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [532]
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,707
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Research works printed but not linked: 1
- Safer D. J., 1971, Biol. Psychiatry, 3, 347
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“531 Ladostigil ( 46 ), an AChE/MAO-B inhibitor developed through a pharmacophore fusion strategy, 532 has completed a clinical phase II trial (NCT01429623).”
BackgroundAsim, A., Jastrzębski, M. K., & Kaczor, A. A. (2025) · Molecules · doi:10.3390/molecules30142975 · Cited by 46
“A dual AChE/MAO-B inhibitor called ladostigil has completed its phase-II trial and been declared to be non-toxic and well-tolerated among the patients [148].”
Melfi, F., Carradori, S., Angeli, A., & D’Agostino, I. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2226860 · Cited by 25
“Conjugated derivatives of the chroman-4-one nucleus (resembling chalcones) were studied as dual-targeted inhibitors affording interesting SARs data (Figure 17a) [115,116].”
BackgroundInnovative pathological network‐based multitarget approaches for Alzheimer's disease treatment
Mayo, P., Pascual-Guerra, J., Crisman, E., Domínguez, C., López, M. G., & Leon, R. M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22045 · Cited by 20
Thakur, A., Rana, M., Vanjani, S., Liou, K.-C., Taliyan, R., Nepali, K., & Yang, C. (2026) · Medicinal Research Reviews · doi:10.1002/med.70047 · Cited by 12
Sharma, M. R., Thakur, S., Jadhav, H. R., & Bharate, S. B. (2023) · ChemistrySelect · doi:10.1002/slct.202301879 · Cited by 10
Zhu, X., Lv, Y., Fan, M., Guo, J., Zhang, Y., Gao, B., Zhang, C., & Xie, Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106817 · Cited by 9
Małecka, M., Sobiesiak, M., Chęcińska, L., Kozakiewicz, A., Napiórkowska-Mastalerz, M., Ziomkowska, B., Stępniak, A., & Kupcewicz, B. (2023) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2023.123715 · Cited by 9
Du, W.-R., Wang, Y., Zhou, X.-W., Lan, Y. J., Wei, B.-B., Guo, X.-Y., Wang, X., & Ma, Z.-Y. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03387-4 · Cited by 6
“1 [11 – 14].”
Wu, X., Ze, X., Qin, S., Zhang, B., Li, X., Gong, Q., Zhang, H., Zhu, Z., & Xu, J. (2024) · Molecules · doi:10.3390/molecules29081782 · Cited by 6
“After receiving nerve signals, it is released into the synaptic space and binds to cholinergic receptors, thus realizing the conduction of cholinergic nerve signals between different neurons [36–38].”
Self-citationKholardi, I. A., Moghaddam, A. H., Bigdeli, M. R., & Jelodar, S. K. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.10.010 · Cited by 5
Álvarez-Valle, J., Fernández, S., Merino‐Robledillo, C., Funes‐Ardoiz, I., Sampedro, D., & Santamarı́a, J. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c03812 · Cited by 4
Hu, Z., Zhou, S., Li, J., Li, X., Zhou, Y., Zhu, Z., Xu, J., & Liu, J. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0206 · Cited by 1
Self-citationLiu, Y., Jiang, Z., Chen, D., He, Z., Ning, W., Wang, S., & Guan, L. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118670 · Cited by 1
Gao, D.-X., Xiang, Y.-L., Yu, Y., Dong, Z.-C., Liu, L.-J., Pan, B. W., Shi, Y., & Pang, Y. X. (2026) · Zeitschrift für Kristallographie - New Crystal Structures · doi:10.1515/ncrs-2026-0026
Chaurasia, V., Modak, S. D., Singh, G. K., & Modi, G. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.017
Zhao, M., Zheng, Y., AiErken, N., Zhang, J., Mándi, A., Han, H., & Zhang, W. (2026) · ACS Omega · doi:10.1021/acsomega.6c05592
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“The results indicated that the medication was safe, well-tolerated, and had encouraging potential for delaying the progression of AD (245, 246).”
Álvarez-Valle, J., Fernández, S., Merino‐Robledillo, C., Funes‐Ardoiz, I., Sampedro, D., & Santamarı́a, J. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6c02113
Metadata
- Authors
- Li, X., Li, T., Zhan, F., Cheng, F., Lu, L., Zhang, B., Li, J., Hu, Z., Zhou, S., Jia, Y., Allen, S., White, L., Phillips, J., Zhu, Z., Xu, J., & Yao, H.
- Affiliations
- China Pharmaceutical University (CN)
- University of Nottingham (GB)
- UCL School of Pharmacy (GB)
- Corresponding author
- Zhu, Zheying
- Xu, Jinyi
- Yao, Hequan
- ORCID
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-11-16
- Volume
- 13
- Issue
- 23
- Pages
- 3488-3501
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W4309167078
- Cited by
- 18
- References
- 50
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 4 · 2023: 5
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- China Pharmaceutical University
- University of Nottingham
- National Natural Science Foundation of China (81874289)
- ?Double First-Class" University project (CPU2018GY04)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- chromanone derivatives, Alzheimer's disease, multi-target drugs, acetylcholinesterase inhibition, monoamine oxidase B inhibition, peripheral anionic site, mitochondrial dysfunction, amyloid fibril formation, tau phosphorylation, scopolamine-induced cognitive impairment, spatial memory, neuroprotection, donepezil comparison
- MeSH terms
- Acetylcholinesterase, Alzheimer Disease, Animals, Cholinesterase Inhibitors, Chromones, Humans, Monoamine Oxidase Inhibitors, Drug Design, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.